BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 12495570)

  • 1. Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold.
    Armon C; Guiloff RJ; Bedlack R
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Sep; 3(3):109-12. PubMed ID: 12495570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [What are the etiological medical therapies in amyotrophic lateral sclerosis?].
    Dib M
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S215-4S219. PubMed ID: 17128114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000.
    Traynor BJ; Alexander M; Corr B; Frost E; Hardiman O
    J Neurol; 2003 Apr; 250(4):473-9. PubMed ID: 12700914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies about databases.
    Swash M
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Sep; 3(3):107. PubMed ID: 12495569
    [No Abstract]   [Full Text] [Related]  

  • 6. What has changed with riluzole?
    Meininger V; Lacomblez L; Salachas F
    J Neurol; 2000 Dec; 247 Suppl 6():VI/19-22. PubMed ID: 19714404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward more efficient clinical trials for amyotrophic lateral sclerosis.
    Cudkowicz ME; Katz J; Moore DH; O'Neill G; Glass JD; Mitsumoto H; Appel S; Ravina B; Kieburtz K; Shoulson I; Kaufmann P; Khan J; Simpson E; Shefner J; Levin B; Cwik V; Schoenfeld D; Aggarwal S; McDermott MP; Miller RG
    Amyotroph Lateral Scler; 2010 May; 11(3):259-65. PubMed ID: 19961263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Riluzole as a treatment for amyotrophic lateral sclerosis].
    Borrás-Blasco J; Plaza-Macías I; Navarro-Ruiz A; Perís-Martí J; Antón-Cano A
    Rev Neurol; 1998 Dec; 27(160):1021-7. PubMed ID: 9951030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What has changed with riluzole?
    Meininger V; Lacomblez L; Salachas F
    J Neurol; 2000 Dec; 247():19-22. PubMed ID: 11200701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rilutek (Riluzole) may extend survival in amyotrophic lateral sclerosis.
    J Neurosci Nurs; 1996 Aug; 28(4):275. PubMed ID: 8880606
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole.
    Paillisse C; Lacomblez L; Dib M; Bensimon G; Garcia-Acosta S; Meininger V
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2005 Mar; 6(1):37-44. PubMed ID: 16036424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole.
    Sívori M; Rodríguez GE; Pascansky D; Sáenz C; Sica RE
    Medicina (B Aires); 2007; 67(4):326-30. PubMed ID: 17891927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis.
    Turner MR; Bakker M; Sham P; Shaw CE; Leigh PN; Al-Chalabi A
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Mar; 3(1):15-21. PubMed ID: 12061944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS].
    Couratier P; Druet-Cabanac M; Truong CT; Bernet-Bernady P; Dumas M; Vallat JM; Preux PM
    Rev Neurol (Paris); 2000 Apr; 156(4):357-63. PubMed ID: 10795012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
    IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motor neuron disease: systematic reviews of treatment for ALS and SMA.
    Orrell RW
    Br Med Bull; 2010; 93():145-59. PubMed ID: 20015852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adverse efects of riluzole (Rilutek) in the treatment of amyotrophic lateral sclerosis].
    Roch-Torreilles I; Camu W; Hillaire-Buys D
    Therapie; 2000; 55(2):303-12. PubMed ID: 10967703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The advance in the research and therapeutic trials of amyotrophic lateral sclerosis].
    Moriwaka F; Tashiro K
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1258-60. PubMed ID: 11464472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment.
    Andreadou E; Kapaki E; Kokotis P; Paraskevas GP; Katsaros N; Libitaki G; Zis V; Sfagos C; Vassilopoulos D
    Clin Neurol Neurosurg; 2008 Mar; 110(3):222-6. PubMed ID: 18055102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-modifying drug therapies.
    Brooks BR; Sanjak M
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():68-75. PubMed ID: 15512878
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.